Skip to content

US · RXRX · BIOTECHNOLOGY

Recursion Pharmaceuticals, Inc. (RXRX) intrinsic value and stock valuation

$2.45as of 2026-11-21 · Mkt cap 1.66B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Recursion Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values RXRX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from RXRX’s statements →

Recursion Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Salt Lake City, UT 84101 recursion.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$74.7M+85.4% 5y CAGRd
20192025
Net income
-$-644.76M
20192025
Free cash flow
-$-378.28M
20192025
Total equity
$1.13B
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$74.7M$58.8M$43.9M$39.7M$10M
Operating income-$-648.13M-$-479M-$-350.06M-$-245.73M-$-182.78M
Net income-$-644.76M-$-463.66M-$-328.07M-$-239.48M-$-186.48M
EPSd-$-1.44M-$-1.69M-$-1.58M-$-1.36M-$-1.1M
Operating cash flow-$-371.81M-$-359.17M-$-287.78M-$-83.52M-$-158.61M
Capital expenditure-$-6.47M-$-13.7M-$-11.96M-$-37.36M-$-39.8M
Free cash flow-$-378.28M-$-372.87M-$-300.33M-$-120.88M-$-198.41M
Total assets$1.47B$1.45B$653.7M$701.3M$610.4M
Total debt$78M$108.5M$50.7M$51M$11.5M
Net debt-$-665.33M-$-485.86M-$-340.89M-$-498.91M-$-273.64M
Total equity$1.13B$1.03B$463.4M$485.8M$542.9M
Cash and short-term investments$743.3M$594.4M$391.6M$549.9M$516.6M
Income statement
20252024202320222021
Revenue$74.7M$58.8M$43.9M$39.7M$10M
Cost of revenue$121M$45.2M$42.6M$48.3M$0.00
Gross profit-$-46.27M$13.6M$1.29M-$-8.59M$10M
Research and development expenses$425.3M$314.4M$241.2M$155.7M$135.3M
Selling, general and administrative expenses$176.6M$178.2M$110.8M$81.6M$57.7M
Other expenses$0.00$0.00-$-700K-$-160K-$-180K
Operating expenses$601.9M$492.6M$351.4M$237.1M$192.8M
Cost and expenses$722.8M$537.8M$393.9M$285.4M$192.8M
Interest income$22.8M$15.8M$19.1M$6.25M$70K
Interest expense$1.81M$1.57M$100K$60K$2.95M
Depreciation and amortization$83.7M$36.5M$24.4M$11.8M$8.4M
Ebitda-$-559.38M-$-426.72M-$-307.63M-$-227.66M-$-175.12M
Operating income-$-648.13M-$-479M-$-350.06M-$-245.73M-$-182.78M
Total other income/expenses, net$3.24M$14.2M$17.9M$6.25M-$-3.7M
Income before tax-$-644.89M-$-464.79M-$-332.13M-$-239.48M-$-186.48M
Income tax expense-$-140K-$-1.13M-$-4.06M$0.00$0.00
Net income-$-644.76M-$-463.66M-$-328.07M-$-239.48M-$-186.48M
Weighted average shares outstanding$447.5M$274.2M$207.9M$175.5M$170.3M
Weighted average diluted shares outstanding$447.5M$274.2M$207.9M$175.5M$170.3M
Balance sheet
20252024202320222021
Cash and short-term investments$743.3M$594.4M$391.6M$549.9M$516.6M
Net receivables$24.7M$49.2M$3.09M$2.75M$9.09M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$812.9M$714.3M$438.1M$569.8M$534.7M
Property, plant and equipment, net$169.5M$233.2M$120.2M$121.5M$64.7M
Goodwill and intangible assets$472.1M$484.7M$88.5M$2.11M$2.19M
Long-term investments$0.00$5.63M$0.00$0.00$0.00
Total non-current assets$661.3M$734.3M$215.6M$131.5M$75.6M
Total assets$1.47B$1.45B$653.7M$701.3M$610.4M
Accounts payable$18.1M$21.6M$3.95M$4.59M$2.82M
Short-term debt$21.8M$22.2M$6.16M$6.05M$1.51M
Deferred revenue$37.6M$61.8M$36.4M$56.7M$10M
Total current liabilities$147.7M$187.5M$93.2M$100.3M$46.7M
Long-term debt$56.2M$86.3M$44.5M$45M$9.97M
Deferred revenue, non-current$114M$118.8M$51.2M$70.3M$6.67M
Total non-current liabilities$195.6M$226.3M$97.1M$115.2M$20.8M
Capital lease obligations$59.3M$81.1M$49.5M$50.4M$10.8M
Total liabilities$343.3M$413.8M$190.3M$215.5M$67.4M
Common stock$10K$0.00$0.00$0.00$0.00
Retained earnings-$-2.08B-$-1.43B-$-967.62M-$-639.56M-$-400.08M
Accumulated other comprehensive income (loss)$36.7M-$-7.64M$0.00$0.00-$-130K
Total equity$1.13B$1.03B$463.4M$485.8M$542.9M
Total investments$0.00$5.63M$0.00$0.00$231.5M
Total debt$78M$108.5M$50.7M$51M$11.5M
Net debt-$-665.33M-$-485.86M-$-340.89M-$-498.91M-$-273.64M
Cash flow statement
20252024202320222021
Net income-$-644.76M-$-463.66M-$-328.07M-$-239.48M-$-186.48M
Depreciation and amortization$83.7M$36.5M$24.4M$11.8M$8.4M
Stock-based compensation$111.2M$81.7M$53.5M$27.9M$14.8M
Change in working capital$13.7M-$-38M-$-44.26M$104.9M-$-310K
Accounts receivable$32.9M-$-6.07M-$-7.76M-$0.00$110K
Inventory$0.00$0.00$0.00$0.00$7.83M
Accounts payable-$-2.62M$6.43M-$-990K$1.77M$1.75M
Net cash provided by operating activities-$-371.81M-$-359.17M-$-287.78M-$-83.52M-$-158.61M
Investments in property, plant and equipment-$-6.47M-$-13.7M-$-11.96M-$-37.06M-$-39.8M
Acquisitions, net$0.00$277.1M$1.84M$0.00$232M
Net cash used for investing activities-$-16.87M$260.1M-$-10.23M$193.3M-$-271.74M
Common stock issued$533M$300.4M$128.1M$143.7M$462.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$521.5M$304.1M$140.1M$154.3M$458.5M
Net change in cash$150.9M$201.6M-$-157.69M$263.8M$28.2M
Cash at end of period$753.9M$603M$401.4M$559.1M$295.4M
Operating cash flow-$-371.81M-$-359.17M-$-287.78M-$-83.52M-$-158.61M
Capital expenditure-$-6.47M-$-13.7M-$-11.96M-$-37.36M-$-39.8M
Free cash flow-$-378.28M-$-372.87M-$-300.33M-$-120.88M-$-198.41M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Recursion Pharmaceuticals, Inc.

        Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.

        CEO
        Najat Khan
        Employees
        600
        Beta
        0.99

        Explore

        Frequently asked questions

        What is the intrinsic value of Recursion Pharmaceuticals, Inc. (RXRX)?

        Recursion Pharmaceuticals, Inc. (RXRX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is RXRX undervalued?

        RXRX trades at a price of $2.45 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.